Anticancer activity of glucomoringin isothiocyanate in human malignant astrocytoma cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study with no human data
PubMed 26882972 · doi:10.1016/j.fitote.2016.02.007
What was done
Researchers investigated the in vitro antitumor activity of moringin [4-(α-l-rhamnopyranosyloxy)benzyl isothiocyanate], produced from myrosinase-induced hydrolysis of glucomoringin under neutral pH, in human grade IV astrocytoma CCF-STTG1 cells. They assessed cell death, apoptosis markers (p53, Bax, Bcl-2), oxidative stress regulators (Nrf2, CK2 alpha), and 5S rRNA expression.
What was found
Moringin induced apoptosis in CCF-STTG1 cells via p53 and Bax activation and Bcl-2 inhibition. Higher doses modulated Nrf2 transcription factor and CK2 alpha expression, and a significant reduction in 5S rRNA was observed. The abstract does not report specific numerical values, concentrations, or effect sizes.
Why it matters
The study identifies a potential natural isothiocyanate candidate and characterizes its apoptotic mechanisms in cultured glioblastoma cells.
Limits
This is an in vitro experiment restricted to a single cell line without in vivo animal testing or human data. No quantitative figures or statistical parameters are provided in the abstract, and physiological relevance (such as blood-brain barrier permeability and normal neural cell toxicity) was not evaluated.
Cited by
- supports Myrosinase hydrolyzes glucomoringin in moringa leaves to produce moringin, or 4-(alpha-L-rhamnopyranosyloxy)benzyl isothiocyanate.